The Oral Peptide Breakthrough: What Enlicitide Teaches Us About Testing
FDA’s approval of enlicitide, the first oral PCSK9 inhibitor, shows why macrocyclic peptide structure, formulation, and fit-for-purpose analytical testing must be interpreted as one connected system.